Definitive Healthcare Corp. (NASDAQ:DH) is a leading provider of healthcare commercial intelligence, offering vital data, insights, and analytics to support healthcare organizations in making informed decisions. The company is positioned in a competitive market alongside entities such as Thoughtworks Holding, Inc. (TWKS), LifeStance Health Group, Inc. (LFST), Clearwater Analytics Holdings, Inc. (CWAN), Cytek Biosciences, Inc. (CTKB), and AvidXchange Holdings, Inc. (AVDX).
In an analysis of DH's financial efficiency, its Return on Invested Capital (ROIC) is -76.31%, starkly lower than its Weighted Average Cost of Capital (WACC) of 8.87%. This discrepancy results in a ROIC to WACC ratio of -8.61, signaling that DH is not generating adequate returns to cover its cost of capital. This inefficiency in capital utilization is a significant concern for investors.
Comparatively, Thoughtworks Holding, Inc. (TWKS) presents a ROIC of -3.79% and a WACC of 9.10%, leading to a ROIC to WACC ratio of -0.42. Although this figure is also negative, it is less severe than DH's, indicating somewhat better capital efficiency.
LifeStance Health Group, Inc. (LFST) showcases the least negative ROIC to WACC ratio among the peers at -0.0017, with a ROIC of -0.01% and a WACC of 8.41%. This positions LFST closest to achieving break-even, suggesting a potential for improvement in generating returns relative to its cost of capital.
Other competitors like Clearwater Analytics Holdings, Inc. (CWAN) and Cytek Biosciences, Inc. (CTKB) also exhibit negative ROIC to WACC ratios of -0.041 and -0.54, respectively. Despite being negative, these figures are more favorable compared to DH's -8.61 ratio, underscoring DH's significant challenge in attaining capital efficiency.
